Gilead Science Inc. (GILD)

162 Kommentare / 0 neu
13.01.2014 15:36
#1
Bild des Benutzers Hublot_BB
Offline
Kommentare: 354
Gilead Science Inc. (GILD)

Hallo Community,

Bin seit geraumer Zeit in Gilead Sc. (GILD) investiert. Per Jahresanfang haben diverse Banken eine Hochstufung vorgenommen. Beispiel UBS:

06.01.14 : 12-month rating: BUY - $ 102.00  

Kürzliche News zu Pipeline beinhaltenden Produkten: U.S. FDA Accepts New Drug Application (NDA) for Gilead's Idelalisib for the Treatment of Refractory Indolent Non-Hodgkin's Lymphoma (iNHL).

 

Denke auch diese Firma hat enormes Potenzial. Firma ist gut positioniert und zeigt solide Struktur auf. Spezialisiert sich vorallem in den Bereichen HIV/AIDS. Mal sehen was an der J.P. Morgan Healthcare Conference herauskommt.

watch: www.gilead.com

Gibt es sonst noch jemand, der auf die Aktie aufmerksam wurde?

Aufklappen
19.02.2015 08:01
Bild des Benutzers Hublot_BB
Offline
Kommentare: 354

Bin raus bei 104$. Schien mir gut, da die meisten Märkte um die AZH notieren. 

Habe auch von einem persönlichen Kontakt erfahren, dass der Patentkrieg um GILD noch böse ausgehen könnte. Muss natürlich nicht, aber das Risiko ist mir im Vergleich zur Chance zu hoch. 

Werde hier noch sporadisch News posten.

18.02.2015 11:03
Bild des Benutzers Hublot_BB
Offline
Kommentare: 354

Schöne Erholung, wenn auch wahrscheinlich grösstenteils technisch bedingt. 

AZH mit Harvoni + Sovaldi TRx @10'871 (erstes Mal über 10'000)

16.02.2015 15:03
Bild des Benutzers Hublot_BB
Offline
Kommentare: 354

Gilead Sciences: Hepatitis-C Tracking at High End of Guidance, RBC Says

It’s Friday, which means we have prescription data for the hepatitis-C treatments from Gilead Sciences (GILD).

Total prescriptions of Harvoni came in at 8455, up 10% from the previous week, while combined Harvoni and Sovaldi prescriptions hit 10781, also up 10%, according to an anlyisis of the data from RBC’s Michael Yeeand team. They continue:

Harvoni’s weekly NRx is tracking in line towards 2015E US consensus of ~ $11-12B.

We were looking for combined TRx go keep growing towards 10k/week, so that 2015 HCV could be $11B USA and $14.3B WW (higher end of Gilead’s implied guidance $13-14.5B vs cons $14.6B).

 

12.02.2015 07:53
Bild des Benutzers Hublot_BB
Offline
Kommentare: 354

Gilead Sciences (NASDAQ:GILD) Expects Dramatic Increase In European Patients Treated With Sovaldi

 

Gilead announced it expects the number of patients in Europe treated with its hepatitis C drug Sovaldi to increase significantly in 2015

Gilead Sciences, Inc. (NASDAQ:GILD) announced Tuesday it expects the number of patients in Europe treated with its hepatitis C drug Sovaldi to increase dramatically in 2015. The company also said that it expects approvals for its drug Harvoni – a newer and advanced version of Sovaldi – to come quickly.

Gilead has come under intense fire in the US for charging exorbitant prices for its hepatitis C drugs; Sovaldi costs $84,000 for a 12-week standard course, while Harvoni carries a price tag of $94,500 for a 12-week treatment regimen. Gilead has been justifying the high prices for its drugs by citing the high cure rates the drugs guarantee and the very few side-effects associated with their usage. However, health insurers and pharmacy-benefits managers in the US have been pressurizing the company to offer the treatments at a discounted price that is affordable for a majority of the eligible patient population. After AbbVie Inc introduced a competitive treatment in the form of Viekira Pak late last year, Gilead was forced to offer discounts on its treatments to get them covered by the pharmacy-benefits management companies.

According to estimates from Datamonitor Healthcare, the hepatitis C market is expected to rise dramatically from $2.9 billion in 2013 to $19.2 billion in 2016. The top five markets for hepatitis C in Europe namely Germany, France, Spain, Italy, and the UK accounted for $872 million in 2013.Like in the US, Gilead is also negotiating prices for its hepatitis C treatments in Europe. The company stated that it is ready to offer the drugs at discounted prices in Europe too if it gets a higher volume of patients in exchange.

John Milligan, president and chief operating officer at Gilead, said about the price negotiations in Europe at the BIO CEO & Investor Conference in New York: "This year they will increase that budget allotment fairly dramatically in return for some price/volume concessions. If they commit to certain volumes, we'll commit to certain price concessions.”

Mr. Milligan disclosed that under a temporary utilization program, as many as 17,000 patients suffering from the chronic hepatitis C virus were treated with Gilead’s hepatitis C drug in France in 2014.

He further mentioned that similar steps and agreements have been carried out in Spain and Italy, where the majority of the European hepatitis C population resides."Italy has committed to volumes this year that I believe are about three times the volume they have ever treated," the CEO said.

09.02.2015 07:58
Bild des Benutzers Hublot_BB
Offline
Kommentare: 354

Neuer UBS Research Bericht

AnhangGröße
PDF icon Gilead347.56 KB
08.02.2015 09:12
Bild des Benutzers Domtom01
Offline
Kommentare: 1793
Preisfrage

Es ist eine Diskussion in Gang gekommen, die auch in den USA immer wichtiger wird: Die Frage nach der Bezahlbarkeit von Medikamenten und der "richtige" Preis. Hier droht den überteuerten Medikamenten, bzw. deren Herstellern einiges an Ungemach!

Ich habe mal stellvertretend einen Artikel eingestellt. Möge sich jeder seine Antworten bilden.

http://www.spiegel.de/wissenschaft/medizin/sovaldi-im-check-was-darf-das...

05.02.2015 07:58
Bild des Benutzers Hublot_BB
Offline
Kommentare: 354

Jetzt muss die Aktie schnellstmöglich wieder über die 100$, besser noch über 105$ gebracht werden. Nach Börsenschluss kam wenigstens eine neue gute Nachricht:

Gilead's Harvoni Selected as Cigna Preferred Treatment for Hepatitis C Genotype 1

Cigna Corp. (CI) selected Gilead Sciences Inc.'s (GILD) Harvoni as its only preferred treatment for hepatitis C genotype 1.

Cigna said it plans to "conduct real-world outcomes assessments on existing and new" drugs including Harvoni, "to further develop outcome-based strategies.

Cigna said Cigna Medicare customers will have Harvoni as an additional formulary choice for treatment.

Gilead shares fell Wednesday, a day after the company estimated the discounts it gives on new hepatitis C drugs would more than double this year.

Drug companies typically offer discounts off list prices to win preferential treatment on health-plan formularies. Yet the level of Gilead's price discounts has been an issue for Wall Street, which fears that competition for its hepatitis C drugs, Sovaldi and Harvoni, could blunt a franchise that helped the company double its revenue in 2014.

In December, AbbVie Inc. won approval for rival therapy Viekira Pak, and Merck & Co. has a hepatitis C treatment in the works.

On its earnings call Tuesday, Gilead executives said it was the nature of the payers covering its drugs that was affecting the level of discounting, rather than competition from rival drugs.

04.02.2015 19:05
Bild des Benutzers 2brix
Offline
Kommentare: 2175

Mittwoch, 04.02.2015 - 14:56 Uhr GILEAD SCIENCES - Hammerzahlen, doch die Aktie fälltDie Nummer 1 im Biotech-Bereich hat hervorragende Zahlen vorgelegt. Doch ein vorsichtiger Ausblick lässt die Aktionäre heute ebenfalls vorsichtig werden. Sie verkaufen die Aktie.

 

Man kann es in einem Satz zusammenfassen: Was der Biotech-Branchenprimus Gilead Sciences gestern an Zahlenwerk für das abgelaufene Jahr 2014 vorgelegt hat, sucht im Pharma-/Biotechbereich seinesgleichen. Trotz der mittlerweile stattlichen Größe des Konzerns gelang es den Verantwortlichen den Umsatz von 10,8 Mrd. $ auf 24,5 Mrd. $ mehr als zu verdoppeln. Der Gewinn vervierfachte sich sogar gegenüber 2013 nahezu auf 8,09 $ je Aktie. Der Grund liegt in neu zugelassenen Hepatitis-C-Behandlungen, die auf einen Schlag einen Jahresumsatz von über 10 Mrd. $ erzielten. Gilead ist inzwischen nicht mehr "nur" die Nummer 1 bei HIV-Medikamenten, sondern hat sich mit Sovaldi und Harmoni, so die Namen der neuen Medikamente inzwischen auch die Pole Position im stark wachsenden Hepatitis-C-Segment gesichert. Bei beiden Jahreskennzahlen, Umsatz und Gewinn, toppte Gilead die Analystenschätzungen. Auch hat das Management ein 15 Mrd-$-Aktienrückkaufprogramm angekündigt.

 

Dennoch fällt die Aktie heute in der Vorbörse. Als Grund führen Marktbeobachter den eher konservativen Ausblick für das Jahr 2015 an. Gilead gab zwar keine Gewinnprognose ab, stellte aber Erlöse zwischen 26,0 und 27,0 Mrd. $ in Aussicht. Die Bruttomarge dürfte zwischen 87 und 90% liegen.

Auf Basis der aktuellen Factset-Schätzungen erwarten Analysten in diesem Jahr einen Umsatz von rund 28,5 Mrd. $ und einen Gewinne je Aktie von 9,85 $. 2016 sollen es 30,2 Mrd $ und beim Gewinn 10,90 $ je Aktie sein. Gilead liegt damit also unter den Analystenprognosen, was der Markt (zunächst) abverkauft.

Technisch bewertet steht die Aktie ähnlich wie der komplette Biotech-Index kurzfristig auf der Kippe. Kann das Zwischentief bei 101,07 $ per Tagesschlusskurs nicht gehalten werden, wäre ein kleines Doppeltop aktiviert, welches zu einem Rücksetzer auf den EMA200 bei 95,40 $ führen könnte. Nur ein Anstieg über das Zwischenhoch bei 109,50 $ würde für Entspannung sorgen. Ein erster Schritt dahin wäre ein bullishes Intraday-Reversal nach dem voraussichtlich sehr schwachen Start.

 

Quelle: http://www.godmode-trader.de/analyse/gilead-sciences-hammerzahlen-doch-d...

04.02.2015 19:01
Bild des Benutzers 2brix
Offline
Kommentare: 2175

mats hat am 04.02.2015 - 17:21 folgendes geschrieben:

Also, ich würde die Firma nicht anrühren Gilead sc. wird meiner Meinung nach den Benchmark Biotech nicht übertreffen und schon der ganze Sektor steht eher auf wackligen Beinen...

was bzw wie meinst du das mit "Benchmark Biotech nicht übertreffen"?
 

Die Zahlen sind doch genial und jetzt noch Dividende und Rückkaufprogramm.  Kenne echt nicht gerade viele Firmen, die das in der heutigen Zeit in solchem Ausmass hinkriegen.

04.02.2015 18:17
Bild des Benutzers Hublot_BB
Offline
Kommentare: 354

GILD ist sauber wie eine Firma nur sein kann. Die Aktie der Firma aber unverschämt. Verfolge die Entwicklung nun seit 2012 und erst seit Kurzem ist das eine Panik-Aktie. Schade um die Firma dahinter, die 130% rev growth YoY liefert.
Buy the rumor ist hier die Devise.

04.02.2015 17:21
Bild des Benutzers mats
Offline
Kommentare: 1238

Also, ich würde die Firma nicht anrühren Gilead sc. wird meiner Meinung nach den Benchmark Biotech nicht übertreffen und schon der ganze Sektor steht eher auf wackligen Beinen...

04.02.2015 16:53
Bild des Benutzers 2brix
Offline
Kommentare: 2175

genau einfach nur lächerlich. Hab mir auch nochmals eine Tranche gekauft. Diese ist auch für einen schnellen Rebound gedacht...so zb 109-110$. Den Rest behalte ich längerfristig.

04.02.2015 15:49
Bild des Benutzers Hublot_BB
Offline
Kommentare: 354

Lächerlich. Einer der besten ER's dieses Jahr und -10%...

Ich kauf nochmals nach und verkaufe dann um die 105$. Hab' genug davon. Sind mir einfach zu viele wacklige Hände dabei.

04.02.2015 08:17
Bild des Benutzers Hublot_BB
Offline
Kommentare: 354

Hab' da noch was gefunden, was den Dip erklären könnte. Wenns aber daran liegt, weiss ich auch nicht mehr. Es wurden einige Deals abgeschlossen, natürlich mit Discount. Dass Analysten das nicht wissen...

 

" With Gilead reporting strong results for the fourth quarter, why would shares drop in after-hours trading? The answer lies in the company's outlook for this year.

The biotech projects net product sales of $26 billion to $27 billion. That reflects an increase over the $24.474 in product sales reported for 2014. However, Wall Street was expecting revenue (which includes both product sales and other sources such as royalties) of $28.65 billion. Gilead might have leaned toward a conservative outlook, but investors hoped for stronger growth.

Some will probably fret about Gilead's forecast for hepatitis C franchise sales growth. Long-term investors, though, will focus on the generally positive business fundamentals for the company, combined with its attractive valuation -- and breathe easy. "

04.02.2015 07:58
Bild des Benutzers Hublot_BB
Offline
Kommentare: 354

Die Firma ist alles andere als berechenbar, das geb' ich zu. DENNOCH:

- Das Volumen im After Hour Market ist sehr dürftig. Warten wir den Handel ab.

- Die Erwartungen wurden deutlich übertroffen. Gilead geht es gut, die Firma steht solide da. Ansonsten hätte man nicht ein BuyBack-Program und eine Quartalsdividende angekündigt. 

 

Falls wir heute tiefere Kurse sehen, werde ich definitiv nachkaufen. 

04.02.2015 07:49
Bild des Benutzers 2brix
Offline
Kommentare: 2175

Eitaro hat am 04.02.2015 - 07:41 folgendes geschrieben:

Erwartungen übertroffen, Buyback von 15 Milliarden angekündigt, erstmalige Quartalsdividende von 43 cents ab Q2…

Nachbörslich -4.5%!!!! Werde nicht schlau aus dieser Firma! Verfolge das Geschehen momentan von der Seitenlinie!

102.35

da haben wohl einige noch mehr erwartet.

Mir solls recht sein, hab mich gestern nicht getraut um nachzukaufen, werde ich ggf heute noch machen.

 

Weiss jemand wann die Quartalsdividende ausbezahlt wird?

 

04.02.2015 07:41
Bild des Benutzers Eitaro
Offline
Kommentare: 37

Erwartungen übertroffen, Buyback von 15 Milliarden angekündigt, erstmalige Quartalsdividende von 43 cents ab Q2…

Nachbörslich -4.5%!!!! Werde nicht schlau aus dieser Firma! Verfolge das Geschehen momentan von der Seitenlinie!

03.02.2015 22:15
Bild des Benutzers Hublot_BB
Offline
Kommentare: 354

+ Dividende und Mrd.-Rückkaufprogramm angekündigt!

03.02.2015 22:09
Bild des Benutzers Hublot_BB
Offline
Kommentare: 354

Yeeeeeeeess! EPS 2.43 vs 2.21 est. & Sales 7.31B vs 6.74B est.

03.02.2015 09:08
Bild des Benutzers 2brix
Offline
Kommentare: 2175

Hublot_BB hat am 03.02.2015 - 08:49 folgendes geschrieben:

2brix hat am 03.02.2015 - 08:25 folgendes geschrieben:


wann kommen denn die Zahlen heute? Vor Start, währenddessen oder After Houre?

5 Minuten ach Börsenschluss der Amis soviel ich weiss

"Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its fourth quarter and full year 2014 financial results will be released on Tuesday, February 3, at 4:05 p.m. Eastern Time."

vielen Dank Hublot_BB.

Bin echt gespannt...hmm weiss nicht recht, evt kaufe ich heute nochmals einige Stücke. Gehe eigentlich eher davon aus, dass die Zahlen besser sind als erwartet. Aber wer weiss? wir werdens sehen.

03.02.2015 08:49
Bild des Benutzers Hublot_BB
Offline
Kommentare: 354

2brix hat am 03.02.2015 - 08:25 folgendes geschrieben:


wann kommen denn die Zahlen heute? Vor Start, währenddessen oder After Houre?

5 Minuten ach Börsenschluss der Amis soviel ich weiss

"Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its fourth quarter and full year 2014 financial results will be released on Tuesday, February 3, at 4:05 p.m. Eastern Time."

03.02.2015 08:25
Bild des Benutzers 2brix
Offline
Kommentare: 2175


wann kommen denn die Zahlen heute? Vor Start, währenddessen oder After Houre?

03.02.2015 08:12
Bild des Benutzers Hublot_BB
Offline
Kommentare: 354

Hepatitis C Drugs Loom Large Over Gilead Results -- Earnings Preview

Gilead Sciences Inc. is scheduled to announce its fourth-quarter earnings Feb. 3. Here is what you need to know:

--EARNINGS FORECAST: Net income of $2.20 a share for the fourth quarter is the consensus of analysts surveyed by Thomson Reuters, compared with 47 cents (diluted EPS; non-GAAP diluted EPS was 55 cents) reported a year earlier. The company did not give guidance for per-share earnings for 2014.

--REVENUE FORECAST: Revenue of $6.7 billion for the fourth quarter is projected by analysts, compared with $3.1 billion in total revenues reported for the period a year earlier.

WHAT TO WATCH:

--NEW HEPATITIS C DRUG LAUNCH: Last year, Gilead's Sovaldi had the top-selling drug launch in history with more than $8.5 billion in sales through the end of September. The fourth-quarter results will give a hint how Gilead's newest hepatitis C pill, Harvoni, approved Oct. 10, will fare. So far, the signs are positive: insurance claims data from Symphony Health Solutions indicate Harvoni's launch during its first 14 weeks on sale is at a higher volume than Sovaldi's.

--HEPATITIS C DISCOUNTING: Harvoni sales face a big challenge that Sovaldi didn't: competition. The Food and Drug Administration approved AbbVie Inc.'s Viekira Pak on Dec. 19. To win business from health plans, both companies are presumed to be offering discounts off their drugs' list prices. The discounts will damp its revenues, which is why it will be worth listening for any indication how much Gilead is discounting Harvoni.

--GILEAD'S OTHER NEW DRUG: Hepatitis C treatment has captured most of the attention as Gilead diversifies beyond HIV/AIDS drugs, but the company has also eyed the cancer market. Last July, the FDA approved Zydelig for treatment of certain blood-cancer patients. Gilead entered a tough market with competition from Johnson & Johnson, and Zydelig carries a Black Box warning regarding the risk for liver and other toxicities, so it will be interesting to see what kind of foothold Gilead is gaining. Analysts project more than $1 billion in yearly sales eventually. 

30.01.2015 14:10
Bild des Benutzers Hublot_BB
Offline
Kommentare: 354

Ich bin seeeehr gespannt auf die Zahlen 14 und Guidance 15. Entweder wirds uns da unter 100 hauen oder aufs nächste Level >110 Smile  Let's rock it GILD !

30.01.2015 13:17
Bild des Benutzers Hublot_BB
Offline
Kommentare: 354

Gilead Sciences, Inc. Continues To Reign Over The Hepatitis C MarketControlling 22% of the US hepatitis C market, Gilead is far ahead of rival AbbVie Inc

Gilead Sciences, Inc. (NASDAQ:GILD) received quite a shock when its rival AbbVie Inc (NYSE:ABBV) went on to take the unusual route of signing an exclusivity pact with the nation’s largest pharmacy-benefits manager Express Scripts Holding Company (NYSE:ESRX), under which Express Scripts agreed to drop Gilead’s hepatitis C drug Harvoni from its list of approved and covered medications and provide an exclusive coverage to AbbVie’s own version of hepatitis C treatment Viekira Pak.

Gilead’s share price took an immediate hit on the news, largely because Gilead depends significantly on its hepatitis C drugs line-up for its revenue. However, the drop in the company’s share price was an overreaction as in the days that followed, it was clear that Gilead will continue to lead the hepatitis C market for a variety of reasons. The company, as per Bloomberg Intelligence, currently controls over 22% of the total hepatitis C market, while AbbVie’s Viekira Pak covers only 6.6%. In other words, Gilead comfortably leads AbbVie in terms of the US hepatitis C lives covered, and as of now, faces little threat from AbbVie in the hepatitis C arena.

Gilead’s continued dominion in the hepatitis C market may be driven by a number of factors, including payers preferring nucleotide-inhibiting drugs or a nucleotide-inhibiting drug-based regime. Yet another reason for the preference could be the ease of the dosing plan; Gilead’s Harvoni is a one-pill-a-day option, while patients on Viekira Pak may require 4-6 pills per day. It is also likely that Gilead offered higher discounts to prescription-benefits managers in exchange for continuing to maintain its leading position in the hepatitis C market. In that case, the company will likely see a contraction in its margins.

Pharmacy-benefits managers are excluding drugs from reimbursements lists in order to obtain greater discounts from manufacturers. Employer clients, who had been hesitant to limit drug choices in the past, have aggressively adopted pharmacy-benefits managers’ reimbursement lists in the face of skyrocketing specialty drug costs. Pharmaceutical giants like Gilead and AbbVie have caught on the trend and are now engaged in a fierce pricing war with each other to have their version of drugs be put on the approved medicines list in return for steep discounts to pharmacy-benefits managers.

Gilead responded to AbbVie’s deal with Express Scripts by locking CVS Health Corp (NYSE:CVS) in a similar exclusivity deal. The agreement with CVS for an exclusive coverage of Harvoni may have given Gilead immediate access to as much as 10% or more of the domestic hepatitis C market.

Furthermore, Gilead's deal with managed healthcare firm Anthem Inc (NYSE:ANTM) for similar exclusive coverage of Harvoni came as nothing less than a huge win for the company; Anthem is one of Express Scripts’ largest customers and the firm’s decision to independently sign a deal with Gilead could lead to other companies following suit.

Anthem as well as other pharmacy-benefits managers who are also now locked into providing exclusive coverage to Gilead’s Harvoni cited the convenience of Gilead’s treatment plan as part of their rationale behind the decision. The fact remains, however, that Gilead may have offered these managers a discount too good to refuse, in exchange for winning exclusivity.

Viekira Pak, as per reports, has seen a 55% growth in its prescriptions; however, this is coming off a weak base – the drug registered just 117 new prescriptions in the second week of January, compared to 1067 new prescriptions for Harvoni in the same time frame, and hence the high growth percentage. The growth rate for Viekira Pak, therefore, on its own cannot be used as a barometer to indicate the company’s ability to garner a greater share of the hepatitis C market.

 

30.01.2015 08:03
Bild des Benutzers Hublot_BB
Offline
Kommentare: 354

Will Gilead Sciences, Inc. (GILD) Be Affected As Missouri Sides With AbbVie (ABBV)?

AbbVie has successfully secured another preferred status for its Hepatitis C treatment, Viekira Pak. The Missouri Medicaid program, a 25-state consortium, signed agreements with the company to make Viekira Pak exclusively available, and to remove Gilead Sciences Inc’s (NASDAQ:GILD) rival treatment, Solavdi, from preferred formulary status.

The agreement shows how different states have joined the pharmacy benefit managers in negotiating and obtaining discounts from Hepatitis C drug makers for expensive treatments in exchange for giving preferred status to the drug. The discount deals began as the two Hepatitis C drug makers, Gilead and AbbVie Inc. (NYSE:ABBV) began striking deals with insurers and pharmacy benefits to get their respective drugs on the formulary lists, while getting the rival treatment removed from the list, in order to ultimately gain a larger market share in the highly lucrative hepatitis C market.  

The discounts offered to the pharmacy benefits and insurers have not been disclosed by either company. The insurers and pharmacy benefits have been urging the drug makers to offer their drugs at a discounted price, since price tags of $83,000-94,500 for the treatment of a single patient are too high.

Under the agreement, 25 states including Missouri, Connecticut, Florida, and New York have signed agreements with AbbVie to make Viekira Pak available to the low-income people covered by Medicaid by replacing Sovaldi as a preferred treatment for Hepatitis C. However, Sovaldi will be administered in certain cases where Viekira Pak is not an effective treatment.

Missouri’s agreement to make Viekira Pak available is expected to save the state $4.2 million in 2016 – a 30-40% cut in the state’s expenditure on Hepatitis C treatments.

Missouri’s Medicaid chief, Joe Parks mentioned that 300 patients are now on the 12-week treatment of Viekira Pak.

A spokeswoman from Gilead mentioned that the company is in discussions with the other 24 states in the consortium for making its treatments available to the patients too, in order to “allow physicians and patients access to a range of choices, rather than having to use a specific regimen.” She further mentioned that the deal only involved Sovaldi and the states are still considering their decisions regarding the improved version of Sovaldi, Harvoni.

According to a report by Morgan Stanley, “Medicaid numbers are too small to have a material impact.” The report suggests that the deal between AbbVie and Missouri Medicaid will result in a headwind of approximately $300 million to Gilead.

Gilead enjoyed an unrivaled position in the Hepatitis C market till AbbVie got approval for Viekira Pak in December 2014. The first discount deal was struck between AbbVie and Express Scripts Holding Company. That deal came as a harsh blow to Gilead, as it indicated that Gilead’s treatment would not be prescribed by the largest pharmacy benefit manager in the US, which covers about 90 million people. However, Gilead managed to offset the impact by signing deals with the other major pharmacy managers, and is currently dominating the Hepatitis C market.

Since it’s only been a month since the rivals got into this intense battle, it’s a little early to predict the outcome. However, the prescriptions data for the past two weeks presents some interesting insights into the ongoing competition.

29.01.2015 16:32
Bild des Benutzers Hublot_BB
Offline
Kommentare: 354

Gilead Sciences, Inc. Harvoni Gets Preferred Status From UnitedHealth Group (UNH)

US insurer, UnitedHealth Group Inc. (NYSE:UNH) has decided to back Gilead Sciences, Inc.'s (NASDAQ:GILD) Harvoni as a preferred treatment option for hepatitis C. This gives Gilead a significant lead in the price war with AbbVie Inc (NYSE:ABBV).

Gilead’s hepatitis C treatments, Harvoni and Sovaldi and AbbVie’s Viekira Pak are the first breakthrough drugs to offer high cure rates for hepatitis C, giving power to the two drug-makers to demand high rates for their novel treatments. Gilead’s Harvoni, which is an improved version of Gilead’s Sovaldi, is priced at $94,500 for a 12-week treatment and AbbVie’s Viekira Pak costs $83,300 for a 12-week course.  

However, pharmacy benefit managers (PBM) were not slow in responding to the high prices. US PBMs are strongly opposed to the high pricing strategy of both drug-makers, forcing the companies to offer significant discounts in return for granting preferred or exclusive status to their hepatitis C drugs on their coverage plans.

AbbVie initiated the ongoing price war when it struck a deal with the largest US PBM, Express Scripts Holding Company (NYSE:ESRX) in December last year, to garner exclusive status for Viekira Pak. This was in exchange for a significant discount on the drug for the health insurer’s 25 million customer base. The deal challenged Gilead’s blockbuster drugs, Harvoni and Sovaldi. 

Just two days ago, Gilead signed a deal with PBM, EnvisionRx, which exclusively offers Harvoni and Sovaldi on its formulary, and prescribes Viekira Pak only in rare cases. 

Earlier, Gilead signed contracts with various PBMs including Humana Inc (NYSE:HUM) and Anthem Inc (NYSE:ANTM) that offer its drug as preferred treatment to almost 30 million hepatitis C patients nationwide. 

Furthermore, Gilead has an advantage because of its exclusivity deal with CVS Health Corp (NYSE:CVS), the second-largest US PBM. It also has Harvoni as a preferred treatment option from the third-largest health insurer, Aetna Inc (NYSE:AET). In comparison, AbbVie has so far signed up with ExpressScripts only. Gilead’s deals with top US PBMs have been successful in helping it maintain a dominant position in the hepatitis C market. UnitedHealth’s coverage policy is yet another milestone that will help Gilead to gain more market share in the lucrative hepatitis C market. 

UnitedHealth updated its coverage policy on Wednesday, effective from Feb 1. As per the updated policy, UnitedHealth will prefer Gilead’s hepatitis C drugs over AbbVie’s Viekira Pak. The policy applies to all UnitedHealth’s commercial customers who are fully insured and use the company’s Optum RX PBM as well as to those who are self-insured, including major employers who use the company’s list of drugs. In addition, the update will also be applicable for UnitedHealth’s Medicaid, Medicare, and military contracts. Gilead, with a large UnitedHealth customer base, will gain access to about 45 million health-plan US customers. Although, out of UnitedHealth’s 45 million medical customers, only 18 million are employed by companies and are self-insured for medical benefits.

29.01.2015 14:48
Bild des Benutzers Hublot_BB
Offline
Kommentare: 354

Needham Ups Sales Estimates Of Hep C Drugs, Says Buy Gilead Ahead Of Q4

 

Gilead Sciences (GILD) will report fourth quarter earnings in early February, and Needham & Co. today boosted their sales estimates for the firm’s hepatitis C drug, reiterating a Buy rating ahead of the report.

Alan Carr and Mark Vignola now expect worldwide fourth-quarter sales of $1.9 billion and $1.28 billion for Sovalid and Harvoni, respectively, up from their previous estimates of $1.7 billion and $970 million. They also noted that there isn’t much visibility to Sovaldi sales outside the U.S. which could provide greater upside to their estimates.

From their note:

Our new 4Q14 total revenue and product sales estimates are $6.23B (was $5.72B) and $6.15B (was $5.65B), respectively. Our new 4Q14 non-GAAP EPS estimate is $2.01 (was $1.78).

Harvoni was approved in Oct 2014 in the U.S. and Nov 2014 in the E.U. Uptake according to IMS/Symphony data has been strong, exceeding that of the Sovaldi launch last year. Our 2015 WW Harvoni estimate is $11.44B. Given superior profile relative to other agents, including Viekira Pak, we expect the drug to hold a dominant share of the market. We expect real-world efficacy and safety data to be generally supportive of Harvoni. Despite recent concerns, payer reimbursement risk appears to be somewhat modest. Gilead has guided for addition of GT3 pts and a 12-wk tx regimen for cirrhotic pts to the Harvoni label later this year.

They reiterated a Buy rating and $120 price target on the stock.

29.01.2015 08:17
Bild des Benutzers Hublot_BB
Offline
Kommentare: 354

Gilead Sciences, Inc. (Nasdaq: GILD) today announced the promotion of Andrew Cheng, MD, PhD to Executive Vice President, HIV Therapeutics and Development Operations, and Taiyin Yang, PhD, to the role of Executive Vice President, Pharmaceutical Development and Manufacturing. Dr. Cheng and Dr. Yang will both join Gilead's senior leadership committee.

Dr. Cheng joined Gilead in 1999. He has led clinical development activities for the company's development-stage programs in HIV/AIDS. In 2009, he was appointed Senior Vice President, HIV Therapeutics and Development Operations, assuming additional responsibility for biometrics, clinical operations, clinical pharmacology, drug safety and public health, project management and regulatory affairs. Dr. Cheng reports to Norbert Bischofberger, PhD, Executive Vice President, Research and Development and Chief Scientific Officer. Prior to joining Gilead, Dr. Cheng trained in internal medicine at the University of California, Los Angeles. He received his medical degree and PhD in Cellular and Molecular Biology from Columbia University and his undergraduate degree from the Johns Hopkins University.

Dr. Yang joined Gilead in 1993 and was promoted to Senior Vice President in 2005. In her newly expanded role, Dr. Yang is responsible for managing pharmaceutical development, analytical operations, laboratory information, quality assurance and manufacturing of both clinical and commercial drug substance and drug product. She reports to Dr. Bischofberger and to John Milligan, PhD, President and Chief Operating Officer. Prior to joining Gilead, Dr. Yang was Director of Analytical Chemistry at Syntex. Dr. Yang received her bachelor's degree in Chemistry from National Taiwan University and her PhD in Organic Chemistry from the University of Southern California.

"Andrew and Taiyin have both demonstrated leadership in bringing groups together to help expedite the development and manufacturing of products -- ultimately allowing the company to reach patients in need more quickly," commented Dr. Bischofberger. "They are experts in their respective fields and have helped build teams that are efficient and highly productive. These promotions recognize their achievements and dedication to bringing innovative new therapies to patients around the world." 

28.01.2015 13:51
Bild des Benutzers Hublot_BB
Offline
Kommentare: 354

Press Release: Gilead Sciences to Release Fourth Quarter and Full Year 2014 Financial Results on Tuesday, February 3, 2015

Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its fourth quarter and full year 2014 financial results will be released on Tuesday, February 3, at 4:05 p.m. Eastern Time. At 4:30 p.m. Eastern Time, Gilead's management will host a conference call to discuss the company's financial results for the fourth quarter and full year 2014 as well as provide a general business update and financial guidance for 2015.

The live webcast of the call can be accessed at the company's Investors page at www.gilead.com/investors. Please connect to the company's website at least 15 minutes prior to the start of the call to ensure adequate time for any software download that may be required to listen to the webcast. Alternatively, please call 1-877-359-9508 (U.S.) or 1-224-357-2393 (international) and dial the participant passcode 56363760 to access the call. Telephone replay will be available approximately two hours after the call through 11:59 p.m. Eastern Time, February 5, 2015. To access the replay, please call 1-855-859-2056 (U.S.) or 1-404-537-3406 (international) and dial the participant passcode 56363760. The webcast will be archived on www.gilead.com for one year. 

Seiten